Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Christoph Funk
Observed names:
C FUNK,
C Funk,
C H Funk,
C. Funk,
Funk, Christoph
Institution:
Justus-Liebig-Universität Gießen
Observed institutions:
F. Hoffmann-La Roche AG,
Inserm,
University of Basel,
Justus-Liebig-Universität Gießen,
Roche (France),
Université Paris Descartes,
Drexel University
show all 7
ORCID:
0000-0001-7388-4415
Observed ORCID:
0000-0001-7388-4415
OpenAlex ID:
A5001393185
Substrate-Dependent Drug-Drug Interactions between Gemfibrozil, Fluvastatin and Other Organic Anion-Transporting Peptide (OATP) Substrates on OATP1B1, OATP2B1, and OATP1B3
2007
·
Johannes Noé
, Renée Portmann
, et al.
·
Drug Metabolism and Disposition
·
316
Cholestatic Potential of Troglitazone as a Possible Factor Contributing to Troglitazone-Induced Hepatotoxicity: In Vivo and in Vitro Interaction at the Canalicular Bile Salt Export Pump (Bsep) in the Rat
2001
·
Christoph Funk
, Christiane Ponelle
, et al.
·
Molecular Pharmacology
·
312
Multi-organ system for the evaluation of efficacy and off-target toxicity of anticancer therapeutics
2019
·
Christopher W. McAleer
, Christopher J. Long
, et al.
·
Science Translational Medicine
·
207
Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate
2001
·
C Funk
, M Pantze
, et al.
·
Toxicology
·
187
Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria
2013
·
Joe Bentz
, Michael P O’Connor
, et al.
·
Drug Metabolism and Disposition
·
165
PDF
A Decade in the MIST: Learnings from Investigations of Drug Metabolites in Drug Development under the “Metabolites in Safety Testing” Regulatory Guidance
2018
·
Simone Schadt
, Bojan Bister
, et al.
·
Drug Metabolism and Disposition
·
132
PDF
Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective
2018
·
J. Gerry Kenna
, Kunal S. Taskar
, et al.
·
Clinical Pharmacology & Therapeutics
·
130
PDF
Pharmacology of Basimglurant (RO4917523, RG7090), a Unique Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator in Clinical Development for Depression
2015
·
Lothar Lindemann
, Richard H. Porter
, et al.
·
Journal of Pharmacology and Experimental Therapeutics
·
117
Metabolic Profiling of Human Long-Term Liver Models and Hepatic Clearance Predictions from In Vitro Data Using Nonlinear Mixed-Effects Modeling
2017
·
Nicole A. Kratochwil
, Christophe Meille
, et al.
·
The AAPS Journal
·
116
PDF
Design, Data Analysis, and Simulation of in Vitro Drug Transport Kinetic Experiments Using a Mechanistic in Vitro Model
2008
·
Agnès Poirier
, Thierry Lavé
, et al.
·
Drug Metabolism and Disposition
·
105
The role of hepatic transporters in drug elimination
2008
·
Christoph Funk
·
Expert Opinion on Drug Metabolism & Toxicology
·
101
Minimizing DILI risk in drug discovery — A screening tool for drug candidates
2015
·
S. Schadt
, S. Simon
, et al.
·
Toxicology in Vitro
·
97
Metabolic Profiles of Minimally Absorbed Orlistat in Obese/Overweight Volunteers
1996
·
Jianguo Zhi
, Angela T. Melia
, et al.
·
The Journal of Clinical Pharmacology
·
97
Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data
2009
·
Agnès Poirier
, Anne-Christine Cascais
, et al.
·
Journal of Pharmacokinetics and Pharmacodynamics
·
83
Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators: Discovery of 2-Chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1 H -imidazol-4-ylethynyl]pyridine (Basimglurant, RO4917523), a Promising Novel Medicine for Psychiatric Diseases
2015
·
Georg Jaeschke
, Sabine Kolczewski
, et al.
·
Journal of Medicinal Chemistry
·
77
Current limitations and future opportunities for prediction of DILI from in vitro
2016
·
Christoph Funk
, Adrian Roth
·
Archives of Toxicology
·
67
Mechanistic Modeling of Hepatic Transport from Cells to Whole Body: Application to Napsagatran and Fexofenadine
2009
·
Agnès Poirier
, Christoph Funk
, et al.
·
Molecular Pharmaceutics
·
66
New strategies to address drug-drug interactions involving OATPs.
2007
·
Agnés Poirier
, Christoph Funk
, et al.
·
PubMed
·
66
New Antibacterial Agents Derived from the DNA Gyrase Inhibitor Cyclothialidine
2004
·
Peter Angehrn
, Stefan Buchmann
, et al.
·
Journal of Medicinal Chemistry
·
62
Climate Vulnerability in Rainfed Farming: Analysis from Indian Watersheds
2018
·
Archana Raghavan Sathyan
, Christoph Funk
, et al.
·
Sustainability
·
60
PDF
Piperidine renin inhibitors: from leads to drug candidates
2001
·
H Märki
, A Binggeli
, et al.
·
Il Farmaco
·
59
Sensitivity analysis of a climate vulnerability index - a case study from Indian watershed development programmes
2018
·
Archana Raghavan Sathyan
, Christoph Funk
, et al.
·
Climate Change Responses
·
51
PDF
The Need for Human Breast Cancer Resistance Protein Substrate and Inhibition Evaluation in Drug Discovery and Development: Why, When, and How?
2014
·
Agnès Poirier
, Renée Portmann
, et al.
·
Drug Metabolism and Disposition
·
51
Are Biotransformation Studies of Therapeutic Proteins Needed? Scientific Considerations and Technical Challenges
2019
·
Simone Schadt
, Simon Hauri
, et al.
·
Drug Metabolism and Disposition
·
50
Calibration of In Vitro Multidrug Resistance Protein 1 Substrate and Inhibition Assays as a Basis to Support the Prediction of Clinically Relevant Interactions In Vivo
2014
·
Agnès Poirier
, Anne-Christine Cascais
, et al.
·
Drug Metabolism and Disposition
·
48
Show more works
View as search
Works count:
59
Citation count:
3,297
H-index:
31
I10-index:
40
Year
Topic
Type